These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 29909472)

  • 41. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Finasteride in the treatment of alopecia.
    Libecco JF; Bergfeld WF
    Expert Opin Pharmacother; 2004 Apr; 5(4):933-40. PubMed ID: 15102575
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
    Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
    Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
    Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Finasteride-associated male infertility.
    Chiba K; Yamaguchi K; Li F; Ando M; Fujisawa M
    Fertil Steril; 2011 Apr; 95(5):1786.e9-11. PubMed ID: 21193189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
    Gupta AK; Carviel J; Gupta MA; Shear NH
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
    Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia.
    Irwig MS
    Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):248-53. PubMed ID: 25871957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-finasteride syndrome - does it really exist?
    Maksym RB; Kajdy A; Rabijewski M
    Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Finasteride: a review of its use in male pattern hair loss.
    McClellan KJ; Markham A
    Drugs; 1999 Jan; 57(1):111-26. PubMed ID: 9951956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistent sexual side effects of finasteride: could they be permanent?
    Canguven O; Talib RA
    J Sex Med; 2013 May; 10(5):1441. PubMed ID: 23421328
    [No Abstract]   [Full Text] [Related]  

  • 55. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
    Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
    BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-finasteride syndrome.
    Pereira AFJR; Coelho TOA
    An Bras Dermatol; 2020; 95(3):271-277. PubMed ID: 32317131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study.
    Ali AK; Heran BS; Etminan M
    Pharmacotherapy; 2015 Jul; 35(7):687-95. PubMed ID: 26133534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finasteride for hair loss: a review.
    Gupta AK; Venkataraman M; Talukder M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1938-1946. PubMed ID: 34291720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update.
    Murad A; Bergfeld W
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1385-1390. PubMed ID: 29524253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.